Ondansetron Eg Labo

Ondansetron, the active ingredient in Ondansetron Eg Labo, is a 5‑HT3 receptor antagonist presented as an oral dosage form for oral use. It is used to prevent and treat nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative settings.

GNH USA supplies Ondansetron Eg Labo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Ondansetron is an antiemetic that acts on the serotonin 5‑HT3 pathway to control nausea and vomiting.

- Chemotherapy‑induced nausea and vomiting: reduces frequency and severity of nausea and vomiting in patients receiving cytotoxic chemotherapy. - Radiotherapy‑induced nausea and vomiting: helps control nausea and vomiting associated with radiation treatment. - Postoperative nausea and vomiting: prevents and treats nausea and vomiting after surgical procedures.

Ondansetron may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Diarrhoea: loose stools. - Fatigue: feeling of tiredness. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm, including QT prolongation. - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Serotonin syndrome: agitation, hyperreflexia, tremor when combined with serotonergic agents. - Hepatic dysfunction: elevated liver enzymes. - Blood dyscrasias: neutropenia or thrombocytopenia.

When prescribing ondansetron, several precautions should be considered to ensure safe use. - Cardiac monitoring: assess baseline ECG in patients with known heart disease or electrolyte abnormalities. - Drug interactions: review concomitant serotonergic drugs to avoid serotonin syndrome. - Pregnancy: evaluate risk‑benefit, as safety data are limited. - Breastfeeding: consider potential excretion in milk; weigh benefits to infant. - Renal or hepatic impairment: dose adjustment may be required; monitor function. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and light.

Ondansetron can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Apomorphine: may cause severe hypotension and loss of consciousness. - Certain antiarrhythmics (e.g., quinidine, amiodarone): increase risk of QT prolongation.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise ondansetron plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce effectiveness. - Serotonergic agents (e.g., SSRIs, MAO inhibitors): increase risk of serotonin syndrome. - Triptans (e.g., sumatriptan): potential additive serotonergic effect.